Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Actavis Pre Watson Pharmaceuticals
September 11, 2018
Orexo removes overhang on shares with key court win
July 14, 2015
Interview – Dong-A shifts sights from Korea to the US
February 07, 2013
M&A activity cools in 2012 as break-ups loom
October 04, 2012
Same, same but different Wellbutrin could cause problems for generics companies
September 28, 2012
Supreme Court could be next up in "pay for delay" saga
September 04, 2012
Valeant gears up for another assault on dermatology
July 25, 2012
Takeovers tick up in 2012 but feeding frenzy still some way off
July 17, 2012
Private equity looks to shoot level Par with $1.9bn bid
June 25, 2012
Shire needs pipeline focus to recover from early Adderall blow
April 26, 2012
Watson adds Actavis and now needs to deliver
March 22, 2012
Global growth would be goal of Watson-Actavis tie-up
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 20, 2022
Genetic Medicine: The Next Generation
March 18, 2022
PD(L)anner - March 2022
Editor's Picks
May 05, 2022
Bristol needs to get fresh
May 04, 2022
The next generation of diabetes technology
April 25, 2022
Nkarta: at least as good as Fate, at a tenth of the price
April 26, 2022
How Gal appointment could influence strategy at Novartis
May 01, 2020
US FDA approval tracker: April